Quick Takeaways: Why It Matters? Odacova’s emergence with a 9‑year longitudinal canine dataset (molecular, transcriptomic, metabolic, functional and immune endpoints) positions its bionutrition platform as a rare, biotech‑grade evidence play in the fast‑growing pet longevity sp...
Quick Takeaways: Why It Matters? Presenting full SLAB trial data for GF‑1004 (a SIRT6‑based gene therapy) positions Genflow to seek an animal‑health licensing or co‑development deal in a fast‑growing pet longevity/sarcopenia niche. If the results show meaningful improvements in...
